QUALITY BY DESIGN DRIVEN STATISTICAL SCREENING APPROACH TO SELECT EFFECTIVE VARIABLES FOR THE FORMULATION DEVELOPMENT OF PEGYLATED BILOSOMES FOR AN ANTIFUNGAL DRUG

DEVIKA NAYAK; MAHALAXMI RATHNANAND; VAMSHI KRISHNA TIPPAVAJHALA

doi:10.22159/ijap.2025v17i1.52138

Authors

DEVIKA NAYAK Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA.
MAHALAXMI RATHNANAND Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA
VAMSHI KRISHNA TIPPAVAJHALA Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA.

DOI:

https://doi.org/10.22159/ijap.2025v17i1.52138

Keywords:

Candida albicans, Pegylated bilosomes, Screening, Design of Experiments, Full factorial design

Abstract

Objective: The study aimed to use a quality-by-design approach to screen out the most suitable process and formulation parameters for developing antifungal drug-loaded pegylated bilosomes.

Methods: Thin film hydration technique was used to prepare the formulations. A design experiment [Design Expert^® software; Design of Experiments (DOE)] employing two levels at three factors was used to conduct eight runs to select and screen formulation and process variables. It was assessed for different response variables, such as Particle Size (PS), Polydispersity Index (PDI), Zeta Potential (ZP), and Entrapment Efficiency (%EE). The screened formulation was evaluated for in vitro drug release and kinetic model evaluation.

Results: The significance of each term in the model was evaluated using an Analysis of Variance (ANOVA). Statistical model terms with a significant P-value of less than 0.05 and graphical analysis (Interaction plot, Pareto chart, and 3D plots) generated by DOE version 13 demonstrated that Span 60, Brij C2, and amplitude of 30% were effective variables for formulating pegylated bilosomes with a desirability value of 0.965. The validated formulation showed a PS of 299.1±5.12 nm, PDI of 0.481±0.07, ZP of -36.6±0.55 mV, and %EE of 79.25±2.75. The in vitro release showed a sustained drug release of 55.53±6.75% over 24 h.

Conclusion: Statistical screening approach using a full factorial design can serve as a valuable tool in identifying and screening significant variables for developing antifungal-encapsulated pegylated bilosomes formulations.

Downloads

Download data is not yet available.

References

Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017;3(4):1–29.

Xiao Z, Wang Q, Zhu F, An Y. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: A retrospective study from 2011 to 2017 in a teaching hospital in China. Antimicrob Resist Infect Control. 2019;8(1):1–7.

Lakshmanan A, Ganeshkumar P, Raam Mohan S, Hemamalini M, Madhavan R. Epidemiological and clinical pattern of dermatomycoses in rural India. Indian J Med Microbiol. 2015;33:S134–6.

Aaron D. Candidiasis (Mucocutaneous)-Dermatological Disorders [Internet]. MSD Manual Professional Edition. 2022 [cited 2023 Aug 4]. Available from: https://www.msdmanuals.com/en-in/professional/dermatologic-disorders/fungal-skin-infections/candidiasis-mucocutaneous

Ketoconazole. [Cited 2023 Jul 31]. Available from https://go.drugbank.com/drugs/DB01026.

FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems [Internet]. [cited 2023 Aug 4]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially

Guo F, Wang J, Ma M, Tan F, Li N. Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med. 2015 Apr 1;26(4):1–13.

Saifi Z, Md R, Mir SR, Amin S. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment. J Drug Deliv Sci Technol [Internet]. 2020;57:101634. Available from: https://doi.org/10.1016/j.jddst.2020.101634.

Albash R, Refai H, Abdelbary AA. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil : in- vitro characterization , ex-vivo permeation and in-vivo assessment. Int J Nanomedicine. 2019;14:6555–74.

Alshaer W, Nsairat H, Lafi Z, Hourani OM, Al-Kadash A, Esawi E, Alkilany AM. Quality by Design Approach in Liposomal Formulations: Robust Product Development. Molecules. 2023;28(1).

International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Pharmaceutical Development Q8(R2). 2009.

International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Quality Risk Management Q9. 2005.

Ibrahim MS, Elsayyad NME, Salama A, Noshi SH. Quality by design (QBD) as a tool for the optimization of indomethacin freeze-dried sublingual tablets: In vitro and in vivo evaluation. Int J Appl Pharm. 2021;13(5):160–71.

Woods DC, Lewis SM. Handbook of Uncertainty Quantification. Handbook of Uncertainty Quantification. 2015.

Singh A, Chauhan C. Factorial Designing – An Essential Tool in Pharmaceutical Optimization. YMER Digit. 2022;21(07):519–25.

Dhoot AS, Fernandes GJ, Naha A, Rathnanand M, Kumar L. Design of Experiments in Pharmaceutical Development. Pharm Chem J. 2019;53(8):730–5.

Chinta R, P R. Formulation development of Empagliflozin and Metformin hydrochloride extended release Tablets: Optimization of Formulation using statistical experimental design. Res J Pharm Tech. 2021;14(3):1201–8.

Aziz DE, Abdelbary AA, Elassasy AI. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: in vitro characterization, ex vivo permeation and in vivo skin deposition study. J Liposome Res [Internet]. 2019 Jan 2;29(1):73–85. Available from: https://doi.org/10.1080/08982104.2018.1430831.

El-Nabarawi MA, Shamma RN, Farouk F, Nasralla SM. Bilosomes as a novel carrier for the cutaneous delivery for dapsone as a potential treatment of acne: preparation, characterization and in vivo skin deposition assay. J Liposome Res. 2020 Jan 2;30(1):1–11.

Al-Mahallawi AM, Abdelbary AA, Aburahma MH. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. Int J Pharm. 2015 May 15;485(1–2):329–40.

Dobó DG, Németh Z, Sipos B, Cseh M, Pallagi E, Berkesi D, Kozma G, Kónya Z, Csóka I. Pharmaceutical Development and Design of Thermosensitive Liposomes Based on the QbD Approach. Molecules. 2022;27(5):1536.

Kis N, Kovács A, Budai-Szűcs M, Gácsi A, Csányi E, Csóka I, Berkó S. Investigation of silicone-containing semisolid in situ film-forming systems using QbD tools. Pharmaceutics. 2019;11(12):660.

Shreya AB, Managuli RS, Menon J, Kondapalli L, Hegde AR, Avadhani K, Shetty PK, Kalthur G, Amirthalingam M, Mutalik S. Nano-transfersomal formulations for transdermal delivery of asenapine maleate : in vitro and in vivo performance evaluations. J Liposome Res. 2016;2104.

Waghule T, Dabholkar N, Gorantla S, Rapalli VK, Saha RN, Singhvi G. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach. Biomed Pharmacother [Internet]. 2021;141:111940. Available from: https://doi.org/10.1016/j.biopha.2021.111940.

Miriam Marques S, Shirodkar RK, Kumar L. Analytical ‘Quality-by-Design’ paradigm in development of a RP-HPLC method for the estimation of cilnidipine in nanoformulations: Forced degradation studies and mathematical modelling of in-vitro release studies. Microchem J. 2023;193:109124.

Teaima MH, Alsofany JM, El-Nabarawi MA. Clove Oil Endorsed Transdermal Flux of Dronedarone Hydrochloride Loaded Bilosomal Nanogel: Factorial Design, In vitro Evaluation and Ex vivo Permeation. AAPS PharmSciTech [Internet]. 2022;23(6):182. Available from: https://doi.org/10.1208/s12249-022-02337-2.

El-Shenawy AA, Abdelhafez WA, Ismail A, Kassem AA. Formulation and Characterization of Nanosized Ethosomal Formulations of Antigout Model Drug (Febuxostat) Prepared by Cold Method: In Vitro/Ex Vivo and In Vivo Assessment. AAPS PharmSciTech. 2020;21(1):1–13.

Shinde UA, Shete JN, Nair HA, Singh KH. Design and characterization of chitosan-alginate microspheres for ocular delivery of azelastine. Pharm Dev Technol. 2014;19(7):813–23.

Zafar A, Alruwaili NK, Imam SS, Hadal Alotaibi N, Alharbi KS, Afzal M, Ali R, Alshehri S, Alzarea SI, Elmowafy M, Alhakamy NA, Ibrahim MF. Bioactive Apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment. Saudi Pharm J [Internet]. 2021;29(3):269–79. Available from: https://doi.org/10.1016/j.jsps.2021.02.003

Ani JU, Okoro UC, Aneke LE, Onukwuli OD, Obi IO, Akpomie KG, Ofomatah AC. Application of response surface methodology for optimization of dissolved solids adsorption by activated coal. Appl Water Sci [Internet]. 2019;9(3):1–11. Available from: https://doi.org/10.1007/s13201-019-0943-7.

Abdelbary AA, Abd-Elsalam WH, Al-mahallawi AM. Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: In vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm [Internet]. 2016;513(1–2):688–96. Available from: http://dx.doi.org/10.1016/j.ijpharm.2016.10.006

Araújo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm. 2010;393(1–2):168–76.

De Lima LS, Araujo MDM, Quináia SP, Migliorine DW, Garcia JR. Adsorption modeling of Cr, Cd and Cu on activated carbon of different origins by using fractional factorial design. Chem Eng J [Internet]. 2011;166(3):881–9. Available from: http://dx.doi.org/10.1016/j.cej.2010.11.062

Annadurai G, Ling LY, Lee JF. Statistical optimization of medium components and growth conditions by response surface methodology to enhance phenol degradation by Pseudomonas putida. J Hazard Mater. 2008;151(1):171–8.

Mosallam S, Sheta NM, Elshafeey AH, Abdelbary AA. Fabrication of Highly Deformable Bilosomes for Enhancing the Topical Delivery of Terconazole: In Vitro Characterization, Microbiological Evaluation, and In Vivo Skin Deposition Study. AAPS PharmSciTech. 2021;22(2):1–12.

Albash R, Yousry C, Al-Mahallawi AM, Alaa-Eldin AA. Utilization of PEGylated cerosomes for effective topical delivery of fenticonazole nitrate: in-vitro characterization, statistical optimization, and in-vivo assessment. Drug Deliv [Internet]. 2021;28(1):1–9. Available from: https://doi.org/10.1080/10717544.2020.1859000

Asgharkhani E, Fathi Azarbayjani A, Irani S, Chiani M, Saffari Z, Norouzian D, Akbarzadeh A, Atyabi SM. Artemisinin-loaded niosome and pegylated niosome: physico-chemical characterization and effects on MCF-7 cell proliferation. J Pharm Investig. 2018;48(3):251–6.

Tagami T, Ernsting MJ, Li SD. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Release [Internet]. 2011;154(3):290–7. Available from: http://dx.doi.org/10.1016/j.jconrel.2011.05.020

Caliceti P, Salmaso S, Elvassore N, Bertucco A. Effective protein release from PEG/PLA nano-particles produced by compressed gas anti-solvent precipitation techniques. J Control Release. 2004;94(1):195–205.

Fernandes AV, Pydi CR, Verma R, Jose J, Kumar L. Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers. Brazilian J Pharm Sci. 2020;56:1–14.

Ammar HO, Mohamed MI, Tadros MI, Fouly AA. Transdermal Delivery of Ondansetron Hydrochloride via Bilosomal Systems: In Vitro, Ex Vivo, and In Vivo Characterization Studies. AAPS PharmSciTech. 2018;19(5):2276–87.

Khalil RM, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy HA. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. J Liposome Res. 2019 Apr 3;29(2):171–82.

Jain S, Indulkar A, Harde H, Agrawal AK. Oral mucosal immunization using *glucomannosylated bilosomes. J Biomed Nanotechnol. 2014;10(6):932–47.

Zafar A, Alsaidan OA, Imam SS, Yasir M, Alharbi KS, Khalid M. Formulation and Evaluation of Moxifloxacin Loaded Bilosomes In-Situ Gel: Optimization to Antibacterial Evaluation. Gels. 2022;8(7):418.

Subair TK, Mohanan J. Development of Nano Based Film Forming Gel for Prolonged Dermal Delivery of Luliconazole. Int J Pharm Pharm Sci. 2022;14(2):31–41.

Ramasamy T, Khandasami US, Ruttala H, Shanmugam S. Development of solid lipid nanoparticles enriched hydrogels for topical delivery of anti-fungal agent. Macromol Res. 2012;20(7):682–92.

Naveentaj S, Muzib YI, Radha R. Design and Optimization of Fluconazole-Loaded Pharmacosome Gel for Enhancing Transdermal Permeation and Treating Fungal Infections Through Box-Behnken Design. Int J Appl Pharm. 2023;15(1):131–40.

MD S, Mehaboob SZ, Doddayya H. Preparation and Characterization of Fluconazole Topical Nanosponge Hydrogel. Int J Pharm Pharm Sci. 2024;16(4):18–26.